Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 601–700 of 1,001
Opportunities for treating chronic hepatitis B and C virus infection using RNA interference
Arbuthnot, P. B., Longshaw, V. M., Naidoo, T., & Weinberg, M. S. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00818.x · Cited by 44
Fowler, D. K., Williams, C., Gerritsen, A. T., & Washbourne, P. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1246 · Cited by 43
Intron-Mediated RNA Interference, Intronic MicroRNAs, and Applications
Ying, S.-Y., Chang, C. P., & Lin, S.-L. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-657-3_14 · Cited by 37
Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure
Poller, W. C., Hajjar, R. J., Schultheiss, H.-P., & Fechner, H. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq056 · Cited by 47
“RNAi may also exert serious side effects in vivo under adverse circumstances.(54,55) A mode to switch on/off shRNA expression in thera-”
BackgroundTechnology Insight: therapeutic RNA interference—how far from the neurology clinic?
Gonzalez‐Alegre, P., & Paulson, H. L. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0551 · Cited by 47
Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies
Vorhies, J. S., & Nemunaitis, J. J. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.3.373 · Cited by 43
Rhodopsin-associated retinal dystrophy: Disease mechanisms and therapeutic strategies
Zhen, F., Zou, T., Wang, T., Zhou, Y., Dong, S., & Zhang, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1132179 · Cited by 44
mi RNA s and HIV : unforeseen determinants of host‐pathogen interaction
Swaminathan, S., Murray, D. D., & Kelleher, A. D. (2013) · Immunological Reviews · doi:10.1111/imr.12077 · Cited by 42
“In one landmark study in mice that utilized 49 adeno-associated virus shRNAs (directed to 6 targets within the liver), 36 of these 49 shRNAs were associated with adverse events due to the shRNA itself, including 23 shRNAs, which eventually led to death, mostly due to acute liver failure (124).”
BackgroundAkhtar, S. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.518611 · Cited by 39
“, [26,27]) and iii) saturation of the RNAi machinery [28] such that the actions of other endogenous gene silencing pathways that use the same machinery are altered including that of the non-coding microRNAs and piwi-interacting RNAs (as these alternative gene silencing pathways are not discussed further in this articl…”
BackgroundCao, H., Yu, W., Li, X., Wang, J., Gao, S., Holton, N. E., Eliason, S. L., Sharp, T., & Amendt, B. A. (2016) · Gene Therapy · doi:10.1038/gt.2016.22 · Cited by 42
“Previous studies have indicated that over expression of shRNAs and RNAi hairpin structures could titrate the miR processing machinery and lead to non-specific effects and toxicity 48,54-56 .”
Adeno-Associated Virus-Mediated MicroRNA Delivery and Therapeutics
Xie, J., Burt, D. R., & Gao, G. (2015) · Seminars in Liver Disease · doi:10.1055/s-0034-1397352 · Cited by 45
MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8611-x · Cited by 43
Current Therapeutic Approaches in FSHD
Wang, L. H., & Tawil, R. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200554 · Cited by 42
“One of the limitations of RNA interference approach is its high dose cytotoxicity derived from its off-target effects [61, 62].”
BackgroundSong, M.-S., & Rossi, J. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2013.00301 · Cited by 42
“A model of RNA silencing suggests that the RISC complex can guide target RNA cleavage or translational repression depending on the extent of sequence complementarity between the miRNA and its target (Meister et al., 2004a; Yi et al., 2005; Grimm et al., 2006; Castanotto et al., 2007).”
BackgroundConsidering RNAi experimental design in parasitic helminths
Dalzell, J. J., Warnock, N. D., McVeigh, P., Marks, N. J., Mousley, A., Atkinson, L. E., & Maule, A. G. (2012) · Parasitology · doi:10.1017/s0031182011001946 · Cited by 44
“The literature reveals that RNAi pathway saturation events can have serious global consequences for an organism, through complete dysregulation of small non-coding (nc)RNA (siRNA, miRNA, piRNA etc.) activity (Grimm et al. 2006; Snove and Rossi, 2006; Dalzell et al. 2009; Stefanic et al. 2010).”
BackgroundBiogenesis and function of endogenous and exogenous siRNAs
Snead, N. M., & Rossi, J. J. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.14 · Cited by 42
EFFICIENT INHIBITION OF HEPATITIS B VIRUS REPLICATION IN VIVO USING PEG-MODIFIED ADENOVIRUS VECTORS
Crowther, C. E., Ely, A., Hornby, J., Mufamadi, M. S., Salazar, F. H., Marion, P. L., & Arbuthnot, P. B. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.066 · Cited by 42
“However, higher doses have lethal toxic effects (data not shown), which are likely to result from Ad immunostimulation and saturation of the endogenous miR pathway (Grimm et al ., 2006).”
Self-citationA construct with fluorescent indicators for conditional expression of miRNA
Qiu, L., Wang, H., Xia, X., Zhou, H., & Xu, Z. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-77 · Cited by 41
“First, extremely high levels of shRNA expression should be avoided because such high levels of shRNA can induce non-specific toxicity [17].”
RNA interference in mammals: behind the screen
Campeau, E., & Gobeil, S. (2011) · Briefings in Functional Genomics · doi:10.1093/bfgp/elr018 · Cited by 47
“This problem has been reported both in vitro [88, 89] and invivo [90] and can result in upregulation of genes normally regulated by endogenous miRNAs, causing toxic effects and even lethality in mice [90].”
BackgroundKeck, K., Volper, E. M., Spengler, R. M., Long, D., Chan, C. Y., Ding, Y., & McCaffrey, A. P. (2008) · Molecular Therapy · doi:10.1038/mt.2008.273 · Cited by 40
Barichievy, S., Saayman, S. M., von Eije, K. J., Morris, K. V., Arbuthnot, P. B., & Weinberg, M. S. (2007) · Oligonucleotides · doi:10.1089/oli.2007.0095 · Cited by 40
“…problems have been exacerbated by the recent observation that manipulation of the natural RNAi pathway within mammalian cells can lead to saturation of cellular RNAi components and serious off-target effects, leading in some cases to death in animal studies (An et al., 2006; Grimm et al., 2006).”
Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys
Mockenhaupt, S., Grosse, S., Rupp, D., Bartenschlager, R., & Grimm, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510476112 · Cited by 39
“Examples illustrating these assets are our previous reports of potent and persistent inhibition of hepatitis B virus (HBV) in HBVtransgenic mice, using liver-specific Adeno-associated viral vectors of serotype 8 (AAV8) for shRNA delivery (3, 4).”
BackgroundMethodSelf-citationUsing non-coding small RNAs to develop therapies for Huntington's disease
Zhang, Y., & Friedlander, R. M. (2011) · Gene Therapy · doi:10.1038/gt.2011.170 · Cited by 41
Hean, J., Crowther, C. E., Ely, A., Islam, R. U., Barichievy, S., Bloom, K. M., Weinberg, M. S., van Otterlo, W. A. L., de Koning, C. B., Salazar, F. H., et al. (2010) · Artificial DNA PNA & XNA · doi:10.4161/adna.1.1.11981 · Cited by 39
“Particularly important to advancing use of expressed anti HBV sequences has been the demonstration that over production of anti HBV shRNAs has serious side effects in vivo that may result in fatality.(23) This has prompted development of chemically modified synthetic siRNAs with better stability and safety profiles.”
BackgroundSelf-citationIn Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells
Kaban, K., Şalva, E., & Akbuğa, J. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0633 · Cited by 39
“Recent in vivo studies have shown that the toxic effect of small RNAs appears to be related to saturation of the endogenous micro RNA pathway [38,39].”
Inducible Transgenic Rat Model for Diabetes Mellitus Based on shRNA-Mediated Gene Knockdown
Kotnik, K., Popova, E., Todiraş, M., Mori, M. A., Alenina, N. V., Seibler, J., & Bäder, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005124 · Cited by 42
“It has been shown that at least liver cells may get necrotic, when too many shRNA molecules interfere with the cellular microRNA processing machinery in vitro [19–21] and in vivo [22].”
BackgroundPolymerase II Promoter Strength Determines Efficacy of microRNA Adapted shRNAs
Lebbink, R. J., Lowe, M., Chan, T., Htet, K., Wang, X., & McManus, M. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026213 · Cited by 39
“A number of reports have indicated that expression of shRNAs via polymerase III promoters can cause toxicity in vivo in shRNAexpressing cells [31,32,33], whereas expression of shRNAs from a polymerase II promoter attenuates this effect [32,34].”
BackgroundThe role of microRNAs in HIV-1 pathogenesis and therapy
Swaminathan, S., Murray, D. D., & Kelleher, A. D. (2012) · AIDS · doi:10.1097/qad.0b013e328352adca · Cited by 41
“In one study in mice which utilized 49 adeno-associated virus shRNAs (directed to six targets within the liver), 36 of these 49 shRNAs were associated with an adverse event due to the shRNA itself, including 23 shRNAs that eventually led to death mostly due to acute liver failure a [81].”
BackgroundsiRNA and shRNA screens advance key understanding of host factors required for HIV-1 replication
Kok, K., Lei, T., & Jin, D. (2009) · Retrovirology · doi:10.1186/1742-4690-6-78 · Cited by 39
“Indeed, the forced overexpression of shRNA and siRNA in cells might also have the potential to exhaust the cellular machinery for RNA silencing [17], complicating the interpretation of biological outcomes.”
BackgroundThe role and clinical implications of microRNAs in hepatocellular carcinoma
Zhao, X., Yang, Z., Li, G., Li, D., Zhao, Y. C., Wu, Y., Robson, S. C., He, L., Xu, Y., Miao, R., et al. (2012) · Science China Life Sciences · doi:10.1007/s11427-012-4384-x · Cited by 38
Strategies for short hairpin RNA delivery in cancer gene therapy
Wang, S., Yao, H., & Qin, Z. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903236843 · Cited by 38
“AAV vectors have been used for liver-specific delivery of shRNA genes in mice by tail injection [33,49].”
BackgroundMethodValdmanis, P. N., Gu, S., Chu, K. C., Jin, L., Zhang, F., Munding, E. M., Zhang, Y., Huang, Y., Kutay, H., Ghoshal, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4079 · Cited by 39
“2,7 This is surprising considering that the liver is tolerant to perturbations of key microRNA components, resulting in relatively mild phenotypes in mice with Dicer deficiency that are devoid of microRNAs 8,9 or mice with germline ablation of the predominant liver microRNA, miR-122 10,11 .”
Self-citationMechanism and Method for Generating Tumor-Free iPS Cells Using Intronic MicroRNA miR-302 Induction
Lin, S.-L., & Ying, S. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-083-0_23 · Cited by 43
Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges
Bernardo, B. C., Gregorevic, P., Ritchie, R. H., & McMullen, J. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01090 · Cited by 40
Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy
Isom, L. L., & Knupp, K. G. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01095-6 · Cited by 41
“Viral vectors, even when administered directly in the CNS, can have a broad distribution, leading to increased uptake in the liver [65, 66].”
BackgroundWitting, S. R., Brown, M., Saxena, R., Nabinger, S. C., & Morral, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704178200 · Cited by 40
RNA Inhibition, MicroRNAs, and New Therapeutic Agents for Cancer Treatment
Spizzo, R., Rushworth, D., Guerrero, M., & Calin, G. A. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.030 · Cited by 40
Cytoplasmic RNA viruses as potential vehicles for the delivery of therapeutic small RNAs
Usme-Ciro, J. A., Campillo-Pedroza, N., Almazán, F., & Gallego-Gómez, J. C. (2013) · Virology Journal · doi:10.1186/1743-422x-10-185 · Cited by 39
“therapeutic small RNA delivery because these viruses overcome the main problems that are associated with the saturation of the silencing machinery at the nuclear level [33], Cytoplasmic RNA viruses replicate/transcribe their genomes resulting in high levels of cytoplasmic viral RNA and small regulatory RNAs.”
BackgroundTherapeutic modulation of miRNA for the treatment of proinflammatory lung diseases
Hassan, T. M., McKiernan, P. J., McElvaney, N. G., Cryan, S., & Greene, C. M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.175 · Cited by 41
Basic Principles of RNA Interference: Nucleic Acid Types and In Vitro Intracellular Delivery Methods
Isenmann, M., Stoddart, M. J., Schmelzeisen, R., Groß, C., Bella, E. D., & Rothweiler, R. M. (2023) · Micromachines · doi:10.3390/mi14071321 · Cited by 42
Molecular strategies to design an escape-proof antiviral therapy
Berkhout, B., & Sanders, R. W. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.04.002 · Cited by 41
Saayman, S. M., Arbuthnot, P. B., & Weinberg, M. S. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq460 · Cited by 40
Toward a Durable Anti‐HIV Gene Therapy Based on RNA Interference
Berkhout, B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04972.x · Cited by 37
Cawood, R., Wong, S. L., Di, Y., Baban, D. F., & Seymour, L. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016152 · Cited by 37
Approaches to manipulating microRNAs in neurogenesis
Zhang, H., Shykind, B., & Sun, T. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00196 · Cited by 42
“…needs to be carefully optimized to minimize side effects, for example consistent expression of miRNAs and large amount of short hairpin RNAs (shRNAs) can induce serious liver injury and lead to mouse lethality due to oversaturation of the endogenous small RNA pathways (Grimm et al., 2006).”
BackgroundCardiovascular RNA Interference Therapy: The Broadening Tool and Target Spectrum
Poller, W. C., Tank, J., Skurk, C., & Gast, M. (2013) · Circulation Research · doi:10.1161/circresaha.113.301056 · Cited by 38
Detrimental Effects of RNAi: A Cautionary Note on Its Use in Drosophila Ageing Studies
Alic, N., Hoddinott, M. P., Foley, A., Slack, C., Piper, M. D. W., & Partridge, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045367 · Cited by 37
“This effect appears to be mediated by depletion of the dsRNA processing machinery away from its normal cellular roles such as processing of miRNAs [22].”
BackgroundShariati, L., Rohani, F., Hafshejani, N. H., Kouhpayeh, S., Boshtam, M., Mirian, M., Rahimmanesh, I., Hejazi, Z., Modarres, M., Pieper, I. L., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27253 · Cited by 37
Aurora Kinase B Regulates Telomerase Activity via a Centromeric RNA in Stem Cells
Mallm, J., & Rippe, K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.015 · Cited by 37
Small RNA biology is systems biology
Jost, D., Nowojewski, A., & Levine, E. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.1.11 · Cited by 40
White, M. D., Milne, R. V. J., & Nolan, M. F. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00008 · Cited by 40
“The shRNAs can result in toxicity by disrupting the biogenesis of natural miRNAs (Grimm et al., 2006), causing off-target silencing through accumulation of antisense RNAs (Birmingham et al.”
InfluentialA 21st-century approach to age-old problems: the ascension of biologics in clinical therapeutics
Espiritu, M. J., Collier, A. C., & Bingham, J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.008 · Cited by 40
Jere, D., Kim, J., Arote, R. B., Jiang, H., Kim, Y.-K., Choi, Y. J., Yun, C., Cho, M., & Cho, C. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.005 · Cited by 40
Garraway, S. M., Xu, Q., & Inturrisi, C. E. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123125 · Cited by 37
“In addition, shRNAs derived from adeno-associated virus type 8 can down-regulate liver-derived microRNAs, resulting in fatal liver toxicity within 1 month after intravenous infusion of the vector (Grimm et al., 2006).”
BackgroundBulk, E., Hascher, A., Liersch, R., Mesters, R. M., Diederichs, S., Sargin, B., Gerke, V., Hotfilder, M., Vormoor, J. H., Berdel, W. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2390 · Cited by 37
“Saturation of endogenous silencing pathways has recently been identified as an important source of shRNA-induced toxicity in vivo (31).”
BackgroundLentiviral Vector-Mediated Rnai and Its Use For Cancer Research
Sumimoto, H., & Kawakami, Y. (2007) · Future Oncology · doi:10.2217/14796694.3.6.655 · Cited by 37
“Systemic administration of shRNAAAV vectors resulted in lethal hepatotoxicity, which was not dependent on the target sequence or vectors, but dependent on the levels of shRNA expression, and was associated with the decreased expression of several miRNAs [28].”
BackgroundMicroRNA Interference Technologies
Wang, Z. (2009) · Springer eBooks · doi:10.1007/978-3-642-00489-6 · Cited by 45
Inhibition of miR-21 in glioma cells using catalytic nucleic acids
Belter, A., Rolle, K., Piwecka, M., Fedoruk-Wyszomirska, A., Naskręt-Barciszewska, M. Z., & Barciszewski, J. (2016) · Scientific Reports · doi:10.1038/srep24516 · Cited by 36
Inhibition of highly pathogenic PRRSV replication in MARC-145 cells by artificial microRNAs
Xiao, S., Wang, Q., Gao, J., Wang, L., He, Z., Mo, D., Liu, X., & Chen, Y. (2011) · Virology Journal · doi:10.1186/1743-422x-8-491 · Cited by 36
“On the other hand, shRNA expressing vectors always use Polymerase III promoters, which not only limits tissue-specific expression of shRNA but also has shown to have higher possibilities to induce cellular toxicities due to over expression of shRNA driven by Polymerase III promoters might interfere with endogenous mic…”
BackgroundCharacterization of an HIV-Targeted Transcriptional Gene-Silencing RNA in Primary Cells
Turner, A. W., Ackley, A., Matrone, M. A., & Morris, K. V. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.165 · Cited by 38
“Previous studies have demonstrated that high expression of short hairpin RNA (shRNA) constructs can lead to oversaturation of the endogenous microRNA (miRNA) pathway and result in cellular toxicity (Grimm et al., 2006).”
Sun, D., Rösler, C., Kidd‐Ljunggren, K., & Nassal, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.038 · Cited by 36
“, interferon induction [6]; and by the delivery method itself [7].”
MethodWeak base pairing in both seed and 3′ regions reduces RNAi off-targets and enhances si/shRNA designs
Gu, S., Zhang, Y., Jin, L., Huang, Y., Zhang, F., Bassik, M. C., Kampmann, M., & Kay, M. A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku854 · Cited by 40
Self-citationMicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations
Louten, J., Beach, M., Palermino, K., Weeks, M., & Holenstein, G. (2015) · Biomarker Insights · doi:10.4137/bmi.s29512 · Cited by 38
Khoury, M., Courties, G., Fabre, S., Bouffi, C., Seemayer, C. A., Vervoordeldonk, M. J., Tak, P. P., Jørgensen, C., & Apparailly, F. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27302 · Cited by 36
Arbuthnot, P. B., & Thompson, L.-J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.1670 · Cited by 38
RNA interference-based gene therapy for successful treatment of rheumatoid arthritis
Courties, G., Présumey, J., Duroux-Richard, I., Jørgensen, C., & Apparailly, F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902926089 · Cited by 36
“siRNA: siTNF [15,16] siIL-1β/siIL-6/siIL-18 [18] siRNA or shRNA: siTNF [19,20] LV-shBAFF [21] AAV5-shTNF * *”
BackgroundStringent testing identifies highly potent and escape‐proof anti‐HIV short hairpin RNAs
von Eije, K. J., ter Brake, O., & Berkhout, B. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1329 · Cited by 36
Hibbitts, A., O’Mahony, A., Forde, É., Nolan, L., Ogier, J. R., Desgranges, S., Darcy, R., MacLoughlin, R. J., O’Driscoll, C. M., & Cryan, S. (2014) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2013.1045 · Cited by 36
RNA interference in Pratylenchus coffeae: Knock down of Pc-pat-10 and Pc-unc-87 impedes migration
Joseph, S., Gheysen, G., & Subramaniam, K. (2012) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2012.09.009 · Cited by 35
Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts
Scholefield, J., Watson, L. M., Smith, D. C., Greenberg, J., & Wood, M. J. A. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.39 · Cited by 35
DeWeerdt, S. (2019) · Nature · doi:10.1038/d41586-019-03068-4 · Cited by 35
CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Wu, W.-H., Tsai, Y.-T., Huang, I.-W., Cheng, C.-H., Hsu, C., Cui, X., Ryu, J., Quinn, P. M. J., Caruso, S. M., Lin, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.010 · Cited by 37
GHS-R1a signaling in the DMH and VMH contributes to food anticipatory activity
Merkestein, M., van Gestel, M. A., van der Zwaal, E. M., Brans, M. A. D., Luijendijk, M. C. M., van Rozen, A. J., Hendriks, J., Garner, K. M., Boender, A. J., Pandit, R., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.131 · Cited by 38
Xu, X., Yoo, M., Carlson, B. A., Gladyshev, V. N., & Hatfield, D. L. (2009) · Nature Protocols · doi:10.1038/nprot.2009.145 · Cited by 42
“It should be noted that the highly expressed U6 promoter may cause greater cell toxicity than other promoter”
BackgroundControlling mRNA stability and translation with the CRISPR endoribonuclease Csy4
Borchardt, E. K., Vandoros, L. A., Huang, M., Lackey, P. E., Marzluff, W. F., & Asokan, A. (2015) · RNA · doi:10.1261/rna.051227.115 · Cited by 36
“2014); (ii) spatio-temporal knockdown of overexpressed transgenes in animal models, where RNAi-mediated approaches to knockdown endogenous transgenes might not be effective; and (iii) multiplex processing of noncoding RNAs such as microRNAs without risking saturation of endogenous nucleus-to-cytosol transport machiner…”
BackgroundShang, R., Zhang, F., Xu, B., Xi, H., Zhang, X., Wang, W., & Wu, L. (2015) · Nature Communications · doi:10.1038/ncomms9430 · Cited by 37
“Furthermore, shRNAs can disrupt endogenous miRNA function by competing for protein factors essential for miRNA biogenesis and functions, such as exportin-5, Dicer and Ago proteins, leading to the de-repression of many miRNA-regulated genes 20,21 .”
A Guide to Genome-Wide In Vivo RNAi Applications in Drosophila
Kaya-Çopur, A., & Schnorrer, F. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6371-3_6 · Cited by 40
Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA
Li, H., Okada, H., Suzuki, S., Sakai, K., Izumi, H., Matsushima, Y., Ichinohe, N., Goto, Y., Okada, T., & Inoue, K. (2019) · JCI Insight · doi:10.1172/jci.insight.125052 · Cited by 37
Therapy for prion diseases: Insights from the use of RNA interference
White, M. D., & Mallucci, G. R. (2009) · Prion · doi:10.4161/pri.3.3.9289 · Cited by 37
RNAi as a new therapeutic strategy against HCV
Khaliq, S., Khaliq, S. A., Zahur, M., Ijaz, B., Jahan, S., Ansar, M., Riazuddin, S. A., & Hassan, S. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.08.004 · Cited by 35
Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease☆
Kaucsár, T., Rácz, Z., & Hamar, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.003 · Cited by 38
“Furthermore, it has been reported, that overloading the endogenous miRNA machinery may be harmful, even lethal [73].”
Therapeutic Liver Reconstitution With Murine Cells Isolated Long After Death
Erker, L., Azuma, H., Lee, A. Y., Guo, C., Orloff, S., Eaton, L., Benedetti, E., Jensen, B., Finegold, M., Willenbring, H., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.082 · Cited by 34
siRNAs: their potential as therapeutic agents – Part II. Methods of delivery
Singh, S. K., & Hajeri, P. B. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.002 · Cited by 37
Fighting against kidney diseases with small interfering RNA: opportunities and challenges
Yang, C., Zhang, C., Zhao, Z., Zhu, T., & Yang, B. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0387-2 · Cited by 35
“The observed morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs (through saturation of the endogenous RNAi machinery by the exogenous siRNAs) for the limited cellular factors required for the processing of various small RNAs […”
Viral RNAi Suppressor Reversibly Binds siRNA to Outcompete Dicer and RISC via Multiple Turnover
Rawlings-Goss, R., Krishnan, V., & Walter, N. G. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.02.038 · Cited by 34
“The future of RNAi-based strategies may well be dependent on the ability to control and predict the relative intracellular expression levels of RISC components and potential therapeutics.(40,57) For example, short hairpin RNAs, while shown in vivo to efficiently induce gene silencing, have been found in long-term inve…”
BackgroundIdentifying siRNA-Induced Off-Targets by Microarray Analysis
Anderson, E. M., Boese, Q., Khvorova, A., & Karpilow, J. M. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-191-8_4 · Cited by 34
Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential
Mazzuca, C., Vitiello, L., Travaglini, S., Maurizi, F., Finamore, P., Santangelo, S., Rigon, A., Vadacca, M., Angeletti, S., & Scarlata, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1443297 · Cited by 34
“By incorporating miRNA structures into gene therapy agents, it aims to inhibit the production of the mutant Z-AAT protein and promote the production of functional A1AT (79).”
BackgroundTALEN-Mediated Somatic Mutagenesis in Murine Models of Cancer
Zhang, S., Li, L., Kendrick, S. L., Gerard, R. D., & Zhu, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0529 · Cited by 36
“In addition, shRNAs have many off-target effects that can contribute to tumorigenesis (43, 44).”
Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses
Ivacik, D., Ely, A., Ferry, N., & Arbuthnot, P. B. (2014) · Gene Therapy · doi:10.1038/gt.2014.94 · Cited by 34
Liu, X.-Y., Tang, Q., Chen, H., Jiang, X., & Fang, H. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.5425 · Cited by 33
“That study was supported by the results of further RNA analyses that toxicity and morbidity were correlated with decreased levels of the natural miRNAs miR-122 or let-7a and disruption of their biogenesis and function [49].”
BackgroundResultGermline engineering of the chicken genome using CRISPR/Cas9 by in vivo transfection of PGCs
Challagulla, A., Jenkins, K. A., O’Neil, T. E., Morris, K. R., Wise, T. G., Tizard, M. L., Bean, A. G. D., Schat, K. A., & Doran, T. J. (2020) · Animal Biotechnology · doi:10.1080/10495398.2020.1789869 · Cited by 36
Kotowska‐Zimmer, A., Przybył, Ł., Pewińska, M., Suszyńska-Zajczyk, J., Wronka, D., Figiel, M., & Olejniczak, M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.04.031 · Cited by 37
“By direct comparison of the corresponding shRNA and amiRNA, we confirmed that shRNA can be toxic in vivo, probably due to saturation of the miRNA biogenesis pathway.(45) In contrast, amiR136-A2, which enters the miRNA biogenesis pathway at an early step and generates quantity of mature siRNA approximately 10 times low…”
BackgroundTowards microRNA-based therapeutics for diabetic nephropathy
Alvarez, M. L., & DiStefano, J. K. (2012) · Diabetologia · doi:10.1007/s00125-012-2768-x · Cited by 36
“However, both the toxic side-effects and the risk of over-saturating endogenous small RNA pathways can be minimised by optimising shRNA dose and sequence [69] or by using weaker or tissue-specific promoters [70–72].”
BackgroundKrill, K. T., Gurdziel, K., Heaton, J. H., Simon, D. P., & Hammer, G. D. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1331 · Cited by 36
“Mice injected with short hairpin RNA vectors into the liver exhibit a decrease in the expression of several liver-specific miRNAs, which appears to be a result of oversaturating the endogenous miRNA processing machinery, and evidence of toxicity (39, 40).”
BackgroundRecombinase-based conditional and reversible gene regulation via XTR alleles
Robles-Oteíza, C., Taylor, S., Yates, T. J., Cicchini, M., Lauderback, B., Cashman, C. R., Burds, A. A., Winslow, M. M., Jacks, T., & Feldser, D. M. (2015) · Nature Communications · doi:10.1038/ncomms9783 · Cited by 33
“High expression of a heterologous shRNA could obscure biological readouts by knocking down the expression of unintended mRNA targets or by overwhelming the RNAi processing machinery to such an extent that naturally expressed miRNAs are not normally produced 40-42 .”
Loh, W. P., Yang, Y., & Lam, K. (2017) · Biotechnology Journal · doi:10.1002/biot.201600488 · Cited by 36
RNA interference therapy for glioblastoma
Guo, D., Wang, B., Han, F., & Lei, T. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481667 · Cited by 35
“The findings that the effect was dosedependent and concurrently shRNA sequence-independent indicated that non-specific saturation of endogenous RNAi machinery was the underlying cause of morbidity and mortality [51,70].”
BackgroundBarik, S. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-796 · Cited by 34
Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome
Sun, W.-D., Zhu, X., Li, J., Mei, Y.-Z., Li, J.-H., & Li, J.-H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1410479 · Cited by 40
MicroRNAs and Cancer Therapeutics
Yeung, M. L., & Jeang, K. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0526-2 · Cited by 36
“In that study, overexpression of shRNA led to the oversaturation of the cell’s RNA-transporter protein, Exportin-5, and induced hepatotoxicity in the experimental animals (66).”
Background
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.